Advertisement

International Journal of Clinical Pharmacy

, Volume 40, Issue 4, pp 803–805 | Cite as

Finasteride use during pregnancy and early neonatal outcome: a case report

  • Doua AlSaadEmail author
  • Ben H. Lee
  • Sawsan Al-Obaidly
Commentary

Abstract

The use of antiandrogen drugs such as finasteride during pregnancy may carry the risk of birth defects, especially hypospadias. We report a 39-year-old woman, with 5 weeks unplanned pregnancy, the patient conceived while receiving daily dose of finasteride 2.5 mg for treatment of alopecia. The patient’s partner was concurrently using finasteride for the same purpose. Ultrasound scans including detailed anatomy were normal throughout pregnancy and the fetal gender was detected to be male. The patient had her delivery at 38+5 weeks’ gestation, by elective cesarean section, a male infant with a weight of 3.58 kg and Apgar score of 9 and 10 at 1 and 5-min, respectively. The infant was healthy with no obvious dysmorphic features. In this case report, maternal use of finasteride in early pregnancy was not associated with external genitalia abnormalities of a male baby. Moreover, maternal exposure to the semen of partner who received finasteride did not adversely affect the short term neonatal outcomes. However, absence of apparent neonatal adverse effects in a single case report does not indicate safety of use. Population-based long term neonatal outcomes are yet to be established.

Keywords

Antiandrogen Congenital abnormalities Fetal toxicity Finasteride Pregnancy Type II 5 α-reductase inhibitor 

Notes

Funding

No funding was received for the current work.

Conflicts of interest

Authors declare no conflict with interest.

References

  1. 1.
    Finasteride. Food and Drug Administration (FDA). Jan 2014. Available at: http://www.fda.gov/. Accessed 6th Dec 2017.
  2. 2.
    Herskovitz I, Tosti A. Female pattern hair loss. Int J Endocrinol Metab. 2013;11(4):e9860.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (Finasteride, Dutasteride): a systematic review. J Clin Aesthet Dermatol. 2016;9(7):56–62.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Clark RL, Antonello JM, Grossman SJ, Wise LD, Anderson C, Bagdon WJ, et al. External genitalia abnormalities in male rats exposed in utero to finasteride, a 5 alpha-reductase inhibitor. Teratology. 1990;42(1):91–100.CrossRefPubMedGoogle Scholar
  5. 5.
    Bowman CJ, Barlow NJ, Turner KJ, Wallace DG, Foster PM. Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat. Toxicol Sci. 2003;74:393–406.CrossRefPubMedGoogle Scholar
  6. 6.
    Prahalada S, Tarantal AF, Harris GS, Ellsworth KP, Clarke AP, Skiles GL, et al. Effects of finasteride, a type 2 5-alpha reductase inhibitor, on fetal development in the rhesus monkey (Macaca mulatta). Teratology. 1997;55(2):119–31.CrossRefPubMedGoogle Scholar
  7. 7.
    Pole M, Koren G. Finasteride. Does it affect spermatogenesis and pregnancy? Can Fam Physician. 2001;47:2469–70.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Laborde E, Brannigan E. Effect of 1-mg Dose of Finasteride on Spermatogenesis and Pregnancy. J Androl. 2010;31:e1–2.CrossRefPubMedGoogle Scholar
  9. 9.
    Ahn KH, Shin J, Hong SC, Han JY, Lee EH, Lee JS, et al. Pregnancy outcomes with paternal exposure to finasteride, a synthetic 5-alpha-reductase inhibitor: a case series. J Clin Toxicol. 2015;5(2):248.Google Scholar
  10. 10.
    Overview of off-label use of 5-apha reductase inhibitors in women. Netherland pharmacovigilance center lareb. Apr 2015. Available at: http://www.lareb.nl/?lang=en-GB. Accessed 6th Dec 2017.
  11. 11.
    Sallout BI, Al Wadi KA. Aphalangia possibly linked to unintended use of finasteride during early pregnancy. Ann Saudi Med. 2009;29(2):155.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmacy Department, Women’s HospitalHamad Medical CorporationDohaQatar
  2. 2.Public Health Program, London School of Hygiene and Tropical MedicineUniversity of LondonLondonUK
  3. 3.Neonatal sectionSidra Medical and Research CenterDohaQatar
  4. 4.Weill Cornell Medical CollegeDohaQatar
  5. 5.Feto-Maternal Medicine Unit, Obstetrics and Gynecology Department, Women’s HospitalHamad Medical CorporationDohaQatar

Personalised recommendations